Tenon Medical

TNON

Börsenwert 1,8 Mio. $

~Newly issued patents continue to solidify the company's position as an innovator in the rapidly growing sacro-pelvic fusion market~ ~Portfolio now includes 38 issued U.S. patents and 9 international patents, with 31 applications pending~ ~Company anticipates continued additions to its IP portfolio along with several product launches in the coming quarters~ LOS GATOS, CA / ACCESS Newswire / October 15, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients suffering from certain sacro-pelvic disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has issued 8 new patents to the Company so far in 2026 fiscal year. With these additions, Tenon holds 38 issued U.S. patents and 9 international patents and has 31 U.S. and foreign patent applications pending.

~ SImmetry+ System generated approximately $1.2 million in incremental revenue during limited launch period ~ ~ Company plans to support anticipated demand for the SImmetry+ System by expanding its instrument set inventory as needed ~ ~ New SImmetry+ 3D printed screw is the first component of a next-generation lateral SI joint fusion system, and the first of several Company product launches expected in the coming quarters ~ LOS GATOS, CA / ACCESS Newswire / September 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced the full commercial launch of its new titanium 3D- printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the implant's Alpha launch. The limited Alpha launch, involving existing SImmetry users and new physicians, generated approximately $1.2 million (1) in incremental revenue for a period beginning in late Q4 2025 through Q3 2026.

JERSEY CITY, N.J., Sept. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders has closed its previously announced warrant inducement agreement with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants").

LOS GATOS, CA / ACCESS Newswire / September 14, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced today it has closed its previously announced warrant inducement agreement with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of $2,872,338.58, the exercising holder received new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 858,269 shares of common stock (equal to 150% of the shares of common stock issued in connection with the exercise of the Existing Warrants) with an exercise price of $5.02 per share.

JERSEY CITY, N.J., Sept. 11, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders has entered into warrant exercise agreements with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants").

LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders announced today it has entered into warrant exercise agreements with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of $2,872,338.58, the exercising holders will receive in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 858,269 shares of common stock (equal to 150% of the shares of common stock issued in connection with the exercise of the Existing Warrants) with an exercise price of $5.02 per share.

Shares of Tenon Medical Inc. (NASDAQ:TNON) are trading sharply higher Friday morning, extending a powerful multi-day rally following a major balance sheet restructuring.

Shares of Tenon Medical Inc. (NASDAQ:TNON) are surging Thursday morning after the medical device company announced the full early repayment of its outstanding senior convertible notes, eliminating a major dilutive overhang for shareholders.

~ Company Takes Proactive Step to Strengthen Balance Sheet and Maintain Flexibility to Execute on Continued Business Momentum ~ LOS GATOS, CA / ACCESS Newswire / September 9, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has repaid in full its outstanding original issue discount senior convertible promissory notes (the "Notes"), which were issued with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date. The Notes were issued on March 11, 2026.

$3M Private Placement Offering JERSEY CITY, N.J., Aug. 31, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders closed its previously announced private placement pursuant to securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering.